Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MPL | P40238 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094538 | 0.89 | ADORA3 (0.60) | ADORA3RXFP1MAPTMEN1KMT2A | |
| SCHEMBL18094552 | 0.81 | MAPT (0.52) | ADORA3RXFP1MAPTMPLLMNA | |
| SCHEMBL18094482 | 0.80 | TRPV1 (0.60) | ADORA3RXFP1 | |
| SCHEMBL18094586 | 0.80 | EPHX2 (0.55) | EPHX2MEN1KMT2AMPLTSHR | |
| SCHEMBL16718761 | 0.79 | ADORA3 (0.57) | ADORA3RXFP1MEN1KMT2AKDM4E | |
| SCHEMBL18094561 | 0.78 | ADORA3 (0.56) | NTRK1ADORA3RXFP1MAPTMEN1 | |
| SCHEMBL18094484 | 0.78 | PTGS1 (0.51) | ADORA3RXFP1MAPTMPLLMNA | |
| SCHEMBL18094539 | 0.77 | ADORA3 (0.58) | ADORA3RXFP1MAPTMEN1KMT2A | |
| SCHEMBL16718836 | 0.75 | ADORA3 (0.49) | ADORA3RXFP1MAPTMPLLMNA | |
| SCHEMBL18094541 | 0.75 | TRPV1 (0.54) | ADORA3RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | NTRK1 4861/4885ADORA3 648/4885EPHX2 1037/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | NTRK1 4861/4885ADORA3 648/4885EPHX2 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.